Eli Lilly (LLY) Q4 FY25 earnings call

Eli Lilly delivered strong Q4 FY25 results, driven by robust sales of key products like Mounjaro and Zepbound, alongside significant pipeline advancements and manufacturing expansion. The company is strategically investing in innovation and capacity, with a focus on expanding market access for its incretin portfolio, despite anticipated price erosion in 2026.